Non-interventional Study of Avastin® First-line in Metastatic Colorectal Cancer (Koralle)
N/A
18 Years
N/A
18 Years
N/A
Open (Enrolling)
Both
Colorectal Cancer
Both
Colorectal Cancer
Trial Information
Non-interventional Study of Avastin® First-line in Metastatic Colorectal Cancer (Koralle)
Inclusion Criteria:
- Age >= 18 years
- Patients with metastatic colorectal cancer where investigators have decided to give a
first-line, fluoro-pyrimidine-based combination therapy with Avastin® according to
Summary of Product Characteristics (SmPC)
- Written and signed informed consent prior to onset of documentation
Exclusion Criteria:
- Contraindications for Avastin® according to Summary of Products Characteristics
(SmPC)
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
Differences in progression-free survival of patient subgroups
Outcome Time Frame:
5 years
Safety Issue:
No
Principal Investigator
Clinical Trials
Investigator Role:
Study Director
Investigator Affiliation:
Hoffmann-La Roche
Authority:
Germany: Federal Institute for Drugs and Medical Devices(Bfarm)
Study ID:
ML28120
NCT ID:
NCT01775644
Start Date:
December 2012
Completion Date:
August 2018
Related Keywords:
- Colorectal Cancer
- Colorectal Neoplasms
Name | Location |
|---|
